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Summary 
Fibropapillomatosis (FP) is a neoplastic disease and a most important cause for stranding and 
death of the green turtle chelonia mydas. The Chelonid Herpesvirus 5 (ChHV5) is considered 
its causative agent. Since ChHV5 does not replicate in cell cultures, many questions 
concerning its pathogenesis and epidemiology, including the prevalence among marine turtles 
have not been solved. I developed an ELISA for detecting turtle antibodies against two 
putative ChHV5 envelope glycoproteins (F-US4 and F-US8). To generate standard antisera 
for cut-off values, I produced soluble fragments of these antigens with the aim of using them 
as immunizing antigens in hatchling turtles. To ask from which age on hatchlings would be 
immunocompetent, I developed a second ELISA, suitable for detecting IgY in turtle sera. It 
took several months for them to become capable of mounting antibody responses. Therefore, 
the immunization experiments could not be completed within the time frame of my thesis. I 
tested a panel of sera collected from Australian and Hawaiian green turtles with or without FP 
for antibodies against F-US4 and F-US8. I detected only a few animals (almost exclusively 
with severe FP) with considerable amounts of antibodies against these two antigens and only 
few animals without FP were identified as carriers of antibodies against ChHV5 antigens. My 
data do not agree with the present views concerning the causative link between FP and 
ChHV5 as well as the natural reservoir of ChHV5. 
Keywords: Fibropapillomatosis, Chelonid Herpesvirus 5, ELISA, seroprevalence 
 
Zusammenfassung 
ZusammenfassungFibropapillomatose (FP) ist eine neoplastische Erkrankung und eine der 
häufigsten Todesursachen der grünen Meeresschildkröte chelonia mydas. Das Schildkröten 
Herpesvirus 5 (ChHV5) wird als ursächliches Agens angenommen. Da es sich nicht in 
Zellkulturen repliziert, sind viele Fragen bezüglich Pathogenese und Epidemiologie, so auch 
die Prävalenz des Virus in der Schildkrötenpopulation noch ungeklärt. Ich habe einen ELISA 
zum Nachweis von Antikörpern gegen zwei mutmassliche Hüllenglykoproteine (F-US4 und 
F-US8) entwickelt. Um Standardseren für cut-off Werte zu gewinnen, habe ich lösliche 
Fragmente der beiden Glykoproteine hergestellt, mit dem Ziel, sie in 
Immunisierungsexperimenten an jungen Meeresschildkröten einzusetzen. Der Zeitpunkt der 
Immunokompetenz wurde mit einem zweiten von mir entwickelten ELISA zur Detektion von 
IgY in Schildkrötenseren bestimmt und betrug mehrere Monate nach dem Schlüpfen, weshalb 
die Immunisierungsexperimente während meiner Dissertation nicht beendet werden konnten. 
Ich habe Seren von hawaiianischen, als auch australischen grünen Meeresschildkröten mit 
und ohne FP auf das Vorhandensein von Antikörpern gegen F-US4 und F-US8 getestet. Fast 
ausschliesslich stark an FP erkrankte Individuen, enthielten beachtliche Mengen an 
Antikörpern, und sehr wenige klinisch gesunde Tiere wurden als Antikörperträger 
identifiziert. Diese Daten stellen die ursächliche Verbindung zwischen ChHV5 und FP sowie 
dessen natürliches Reservoir in Frage. 
Keywords: Fibropapillomatose, Schildkröten Herpesvirus 5, ELISA, Seroprävalenz 
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Introduction 
All seven species of marine turtles, including the Green turtle Chelonia mydas, are threatened 
by different factors including urbanization, environmental pollution, entanglement in fishing 
nets, hunting and nest and hatchling depredation by wild (van Mil, 2014, Jones et al., 2015). 
Fibropapillomatosis (FP), a globally distributed, emerging infectious disease, is one of the 
newer threats reported in every species of marine turtles (Herbst, 1994), but most common in 
green turtles (Whitehouse, 2015). It is one of the most important causes for stranding and death 
(Work et al., 2015). FP is a neoplastic disease, characterized by the growth of seemingly benign 
tumors. The tumors emerge predominantly externally on the skin and on mucous membranes, 
where they may reduce vision, obstruct feeding and breathing and affect motion (Work et al., 
2015; Aguirre et al., 2002). Less frequently, internal tumors are also observed, located in heart, 
kidney, intestines, and lungs (Work et al., 2015).  
The Chelonid Herpesvirus 5 (ChHV5) is believed to be the causative agent of FP but the 
expression of the disease may require a multifactorial interplay between ChHV5, environmental 
factors, such as polluted areas (Aguirre and Lutz, 2004), and the host (García-Sastre, Sansonetti, 
2010). A relationship between immunosuppression and FP, causing higher susceptibility to 
secondary infections, has previously been suggested (Work et al., 2001 & 2003). The disease 
is mostly found in juveniles, less commonly in adults (Page-Korjian et al., 2014, Ene et al., 
2005). Prevalence estimates based upon FP records is geographically very variable (Alfaro-
Núñez et al., 2014). Prevalence in Hawaii has decreased since 1990 (Work et al., 2015), 
elsewhere FP has remained stable or even increased (Whitehouse, 2015). However, the way of 
transmission is still not fully understood. Besides direct contact with infected animals, contact 
with Herpesvirus-contaminated substrates or through vectors like parasitic leeches or cleaner 
fishes were suggested (Lu et al., 2000b, Greenblatt, 2004, Whitehouse, 2015). Results of a 
recent study proposed that transmission of the virus depends on superspreaders, a small number 
of highly infectious animals (Work et al., 2015). 
Chelonid herpesvirus 5 is one of six known herpesviruses in chelonids (1, 5 and 6 in marine 
turtles; Tidona, Darai, 2011; Jones et al., 2015). According to its genomic structure, featuring 
a unique long (UL) sequence and a unique short (US) sequence, which is flanked by inverted 
repeats, (Ackermann et al., 2012), ChHV5 belongs to the genus Scutavirus within the 
Alphaherpesvirinae subfamily of the Herpesviridae (Davison and McGeoch, 2010).  
As yet, it has not been possible to make ChHV5 replicate in conventional cell cultures, although 
replicating virus has been detected in the epithelial layer of organotypic raft cultures that 
originated from ChHV5-positive fibroblasts and ChHV5-negative epithelial cells (Work et al., 
2017). Therefore, to date not much is known about the virus itself, its pathogenesis, 
transmission and epidemiology. However, such knowledge is needed in order to understand the 
disease and to develop curative or preventive strategies, like antiviral treatments and/or 
vaccines. Development of serological tools would be particularly important to better understand 
the epidemiology and transmission of the infection and its associated disease.  
In the absence of suitable cell culture systems for serial virus propagation, both virus isolation 
and serum neutralization tests (SNT) cannot be accomplished. Also virus purification for 
conventional ELISA-antigen production is not feasible for the same reason. A previous attempt 
to detecting ChHV5-specific antibodies by ELISA used baculovirus-expressed ChHV5 
glycoproteine H (gH) as an antigen (Herbst et al., 2008). The results showed that captive turtles 
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without previous exposure to FP-animals turned seropositive only after cutaneous tumors had 
appeared as a consequence of inoculation with tumor lysate. These observations suggested that 
both virus replication and tumor development were necessary preconditions for seroconversion. 
However, the same study found also consistently up to 80% seropositive animals among free-
living turtles in Florida, even if they originated from sites without history of FP (Herbst et al., 
2008). Thus, it remained unclear, whether the FP agent ChHV5 itself or a serologically related, 
non-tumor-causing virus was highly prevalent among healthy turtles in Florida.  
As herpesviruses have numerous envelope glycoproteins, each of which having their individual 
evolutionary pressure, we selected two different viral glycoproteins, i.e. F-US4 and F-US8 
(Ackermann et al., 2012), to newly address the question about ChHV5 prevalence among turtles 
with or without FP. Furthermore, we wanted to allow antigen coating under non-denaturing 
conditions. Similar to serological assays for papillomavirus antibodies (Sehr et al, 2001), we 
used Glutathione conjugated to casein as the coating substrate and constructed baculoviruses 
producing soluble fragments of ChHV5 glycoproteins with C-terminal glutathione-S-
transferase (GST) tags. These fusion proteins were expected to bind under native conditions to 
the previously coated glutathione in order to serve there as ELISA antigens.  
As reviewed earlier (Jacobson & Origgi, 2002), sea turtles have at least three classes of 
immunoglobulins, a 17S IgM, a 7S IgY, and a 5.7 S IgY. The 17S antibodies are considered to 
indicate a fresh infection, whereas 7S IgY appear some weeks later and 5.7S IgY emerge only 
several months after the immunogenic event. Ideally, one would look for 17S IgM antibodies 
in order to detect a fresh infection. Unfortunately, specific antibodies against 17 S IgM are not 
commercially available. Yet, monoclonal antibodies against 7S IgY and 5.7S IgY were recently 
developed and made available to us (Work et al., J. Immunol. 2015).  
While these antigens and monoclonal antibodies would provide us with essential tools for 
developing a serological assay, a major problem remained in positive and negative controls. 
According to Herbst and others (2008), turtles raised in captivity without history of FP might 
provide suitable negative control sera. However, no truly positive antisera against either F-US4 
or F-US8 existed at the time. Therefore, we planned for experimental vaccination of 
seronegative turtles, using purified derivates of either F-US4 or F-US8. For this purpose another 
series of baculoviruses was constructed with the aim to produce soluble F-US4 or F-US8 
exodomains, respectively, but this time fused to C-terminal c-myc- and 6xhis-tags. The c-myc-
tag was selected to identify and characterize the expressed protein by making use of a 
commercially available monoclonal antibody against c-myc (Young et al., 2012). The 6xhis-
tag was to be used for purification of these proteins prior to turtle immunization (Dodson et al., 
2007; Young et al., 2012).  
Our permit issued by Australian authorities for vaccinating turtles with our experimental 
vaccines was restricted to the use of turtle hatchlings. However, to date not much is known 
about the development of the immune system in turtles and it was not known at which age, the 
newly born turtles would reach the immunological competence to produce their own antibodies 
upon vaccination. To address this question, we developed an ELISA to test hatchling’s sera for 
the presence and quantity of 7S and 5.7S IgY in their serum. 
Using these approaches, we found that it takes turtles several months following hatching to 
reach a degree of immunological maturity that makes it worthwhile to vaccinate them. The 
antigens intended for use in experimental vaccinations could be purified up to a degree of 
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approximately 80%. Our serological survey using the newly developed ELISAs for detecting 
antibodies against F-US4 and F-US8, respectively, confirmed that captive-reared turtles 
without FP remained seronegative. Yet, in contrast to Herbst (2008), we found that free ranging 
turtles from Hawaii and from Australia exhibited very rarely a strong antibody response against 
either viral protein.  
 
Aims of the present work 
 
The first aim of the present work was to develop an ELISA for detecting turtle antibodies 
against two selected ChHV5 antigens, namely F-US4 and/or F-US8. The assay would then be 
validated by using sera from captive turtles without history of FP as negative controls and sera 
from turtles with FP as potential positive controls. Eventually, consecutive sera from F-US4- 
and/or F-US8-vaccinated turtles would serve as means to establish the cut-off between 
seropositive and seronegative.  
To get new insights into the epidemiology of ChHV5, I wanted to analyze a panel of turtle sera 
from the wild, including samples from areas with reportedly high frequency of FP and from 
areas without history of FP cases. Moreover, I wanted to test sera from animals with various 
degrees of FP. 
Furthermore, I wanted to establish an ELISA for quantifying 7S and 5.7S IgY in the sera of 
hatchlings and juvenile turtles, respectively, and to find the proper developmental stage for 
starting the immunization experiment. A panel of hatchling sera and a panel of juvenile turtle 
sera from various locations in Australia should be used for that purpose.  
Materials and Methods                              Anna Willimann 
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Materials and Methods 
Cloning Strategy   
In order to express differently tagged glycoprotein fragments from a recombinant baculovirus 
vector, the Gateway donor vector pDONR221 was modified to provide an N-terminal 
baculovirus signal sequence and a C-terminal c-myc-GST-tag to our proteins of interest. This 
vector, designated pDONR221-Signal-Bam-Cmyc-GST, was opened by BamHI digestions to 
accommodate our constructs of interest, which were also synthetic and came with BamHI sites 
at both of their designated ends. Once the correct sequence and orientation of the inserted 
fragments had been verified, each construct was transferred by LR recombination to the 
Gateway expression vector pDEST8, which added flanking sequences to the construct that were 
needed for its recombination into the polyhedrin locus of BACMID-cloned baculovirus 
sequences. Finally, baculoviruses were reconstituted by transfecting the BACMID DNAs to 
Sf9 cells.  
Construction of pDONR221-Signal-Bam-Cmyc-GST  
For this purpose, a synthetic sequence was ordered from GenScript 
(http://www.genscript.com), comprising an attB1 sequence, followed by the SP1–2 signal 
peptide sequence (Futatsumori-Sugai and Tsumoto, 2010), a BamHI site, a c-myc-tag, a codon-
optimized GST-sequence, and an attB2 sequence. The fragment was amplified by PCR 
(PHusion DNA Polymerase from Thermo Scientific, Primers were ordered at Microsynth) and 
subsequently gel purified (For Agarose gel electrophoresis, Gene Ruler Mix DNA ladder from 
Thermo Scientific as well as the 1kb DNA ladder from Biolabs were used). In a total volume 
of 8 µl, 150 ng of the PCR product were mixed with 180 ng of purified  pDONR221 DNA (Life 
technologies) and 4.5 μl TE buffer pH 8.0. Then, 2 µl BP clonase II enzyme mix (life 
technologies) was added and the recombination step was carried out according to the standard 
Gateway protocols. The BP recombination reaction facilitates transfer of a gene of interest-in 
this case the attB_Signal_C-myc_GST PCR product-to an attP containing vector as 
pDONR221. Finally, DH5α Chemically Competent E. coli were transformed with the BP 
reaction mix and recombinant progeny was selected on LB containing 50 μg/ml kanamycin. To 
enable selection of entry clones, the pDONR221 vector on the one hand contains a Kanamycin 
resistance gene, on the other hand the two att sites are flanking a cassette containing the ccdB 
gene for negative selection.  
Construction of the entry clones  
Purified pDONR221-Signal-Bam-Cmyc-GST DNA was BamHI (Roche) digested and 
phosphatase-treated (Biolabs). Also the synthetic vectors containing the genes of interest 
(ordered at GenScript) were digested with BamHI. In order to produce the entry clones, T4 
ligations (T4 ligase was purchased from Biolabs) of the BamHI digested vector pDONR221-
Signal-Bam-Cmyc-GST with the inserts flanked by BamHI restriction sites were carried out. 
Afterwards, DH5α Chemically Competent E. coli were transformed with the ligation reactions 
and entry clones were selected on LB containing 50 μg/ml kanamycin.  
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Construction of the expression clones  
DNA of the selected entry clones was extracted and purified. In a volume of 8 µl, 150 ng of the 
entry clone DNA were mixed with 200 ng of purified pDEST8 vector DNA (Life technologies) 
and 5.2 μl TE buffer pH 8.0. Then, 2 µl LR clonase enzyme mix (Life technologies) was added 
and the recombination step was carried out according to the Gateway protocols. The LR 
recombination reaction facilitates transfer of a gene of interest-in this case the attL_Signal_C-
myc_GST cassette containing the synthetic glycoprotein-gene insert - to an attR containing 
Destination vector as pDEST8. Subsequently, DH5α Chemically Competent E. coli were 
transformed with the LR reaction mix and recombinant progeny was selected on LB containing 
100 μg/ml ampicillin. To enable selection of expression clones after Transformation, the 
pDEST8 vector has similar selection properties as the pDONR221 vector used for the BP 
reaction, namely the Ampicillin resistance gene and a ccdB gene flanked by the att sites, 
respectively. 
Production of the bacmid DNA  
The pure expression clones were used to transform MAX Efficiency® DH10Bac™ competent 
cells (Life technologies) for transposition of the genes of interest into the bacmid (Life 
technologies). To identify the colonies containing the recombinant bacmid, an antibiotic 
selection and blue/white screening was used. Kanamycin resistance is conferred by the parent 
bacmid (bMON14272), the helper plasmid (pMON7124) contains the tetracycline resistance 
gene, and the gentamycin resistance gene is carried by the pDEST8 vector. 
Reconstitution of recombinant baculoviruses  
Cell Lines: 
The Sf9 insect cells (Life technologies), used for viral stock production and Endpoint-dilution 
experiments, were cultured in TNM-FH (Grace’s Insect cell medium supplemented (Life 
Technologies) containing 10% FCS). Mimic Sf9 Insect cells (Life technologies) were used for 
protein expression and they were cultured in serum-free medium Sf-900 III SFM (Life 
Technologies). Both cell lines were cultured at 27°C. 
Baculoviruses were reconstituted by transfecting the bacmid DNAs to Sf9 cells. In order to 
generate infectious baculoviruses, purified bacmid DNAs were transfected to Sf9 cells. 1μg of 
DNA and 4μl of the FuGene transfection reagent (Promega) were added to 25 μl of Grace’s 
Insect Medium unsupplemented (life technologies). The whole mix was transferred to a tube 
containing 500 μl of TNM-FH medium (Grace’s Insect cell medium supplemented (Life 
Technologies) containing 10% FCS) and then the mixture was added to 200’000 Sf9 cells 
attached to one well of a 24-well plate. Cells were incubated at 27°C.  After 96 hours medium 
was collected, centrifuged at 1000g, 4°C for 10 minutes. Supernatant was harvested as p0 viral 
stock solution. An Aliquot of 200 μl was frozen down at -80°C for storage, the rest was kept at 
4°C for further propagation of the viral stocks. Transfected cells were detected by means of 
Immunostaining  at different time points post transfection, namely 72 h, 96 h and 120 h. Cells 
were fixed in 4% PFA for 15 minutes, blocked and permeabilised in PBS, 0.1% Triton-X100, 
3% Horse serum and 1% BSA.  Cells were then stained using monoclonal mouse anti V5 
primary antibody (1:500, overnight at 4°C (Invitrogen)) or monoclonal mouse anti C-myc 
primary antibody respectively (1:500, overnight at 4°C (Invitrogen)) and alexa fluor 488 goat-
anti-mouse monoclonal secondary antibody (Life technologies). Nuclei were stained using 
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DAPI (life technologies, 1:1000, incubated for 15 minutes) Green fluorescent cells represent 
infected cells expressing the recombinant protein containing the V5 tag or the C-myc tag 
respectively. 
With the aim of baculoviral p1 amplification, Sf9 cells were infected with the p0 viral stock 
solution and incubated at 27°C. For that purpose, 4 x 106 Sf9 cells cultured in 5 ml TNM-FH 
medium were infected with 100 µl of the p0 viral stock solution and incubated at 27°C. The p1 
viral stock was harvested 7 days after infection. P2 baculoviral amplification was carried out 
the same way using the p1 viral stock solution and Sf9 cells. 
To estimate the viral titer of the p2 viral stock an end-point dilution experiment was carried out. 
For that purpose, Sf9 cells were seeded on a 96-well plate (40’000 cells per well) and infected 
with 100 µl of TNM-FH containing different dilutions of the p2 viral stock ( 1- 10-15) and 
incubated at 27°C for 96 hours before fixing the cells and staining them using the Immune 
Peroxidase technique with the primary antibody anti-V5 mouse mAb (1:1000, 45 minutes at 
37°C) (or anti-C-myc antibody mAb (1:1000, 45 minutes at 37°C)) and the secondary HRP-
linked goat anti mouse IgG (H+L)-HRP (1:1000, 45 minutes at 37°C(thermofisher). As a 
substrate, AEC substrate was used (6% AEC-solution (20mg AEC in 3 ml dimethylformamide) 
in 0.05 M Acetate buffer containing 0.1% H2O2). Red stained cells represented infected cells 
expressing the recombinant protein containing either the V5 tag or the C-myc tag.  
Protein expression and purification  
In order to verify expression of the desired proteins, immunostaining of the fixed cells using 
monoclonal anti-V5 antibody and monoclonal anti-C-myc antibody, respectively, revealed 
presence of the desired protein in Baculovirus-infected cells. Additionally, the secreted form of 
the protein was detected by Western immunoblotting of cell supernatant by staining the PVDF 
membrane with the monoclonal mouse anti-V5 or the monoclonal mouse anti C-myc primary 
antibody (Page Ruler Prestained Protein ladder 10-250K from Thermo Scientific was used for 
PAGE). For detection, the biotinylated horse anti mouse secondary antibody (vector 
laboratories) and the detection system with the Vectastain ABC Kit (Vectastain) and the 
substrate 3, 3’ – Diaminobenzidine tetrahydrochloride (Sigma) were used. Finally, the secreted 
V5-5his-tagged proteins produced for immunizing turtles to generate reference sera were pulled 
down from the supernatant following incubation with magnetic nickel beads (Cube Biotech), 
elution, and Western immunoblotting with anti-V5 antibody. The C-myc-GST-tagged variants 
used as ELISA antigens were not purified.  
Protein production  
For large-scale antigen production, mimic Sf9 cells (obtained from Life technologies) were 
infected with the P2 viral stock solution at an MOI of 5 (4 x 107 cells per T150 flask, 40 ml 
SFM) and incubated at 27°C for 7 days. Protease inhibitor (Complete mini protease inhibitor 
from Roche) was added to the medium after harvesting. 
To further investigate for protein expression and secretion, medium (P3 viral stock) was 
analyzed by Western immunoblotting using the anti-V5 antibody (1:5000) and anti-C-myc 
(1:5000) respectively.  
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Protein Purification  
The secreted protein of the constructs used for immunization were equipped with a C-terminal 
5his tag.  
Cell medium containing the His-tagged proteins were purified using PureCube His Affinity 
MagBeads (Cube Biotech). 
Medium was added 1 in 7 to binding buffer (50 mM NaH2PO4, 300 mM NaCl, 5mM Imidazole, 
10mM β-Mercaptoethanol, pH 8.0) and incubated with the 25 % magnetic bead suspension 
(1ml/50ml diluted medium, equilibrated in 10 ml  binding buffer) at 8°C for 1 hour on an end-
over-end shaker. The tube was then placed on a magnetic stand allowing the beads to separate. 
The supernatant was removed (designated as flow-through fraction). Next, the beads were 
washed twice with washing buffer (10 ml/ 250 μl beads, 50 mM NaH2PO4, 300 mM NaCl, 10 
mM Imidazole, 10mM β-Mercaptoethanol, pH 8.0). The His-tagged protein was eluted using 1 
ml of elution buffer/ 250 μl beads (50 mM NaH2PO4, 300 mM NaCl, 60 mM Imidazole, pH 
8.0). The fractions were analyzed by SDS-PAGE. 
 
ELISA:  
The GST-tagged proteins were used for coating of the ELISA plates. Binding properties were 
tested using the mouse anti C-myc monoclonal antibody. Different antigens were coated and 
sera of animals other than turtles were tested in order to establish the appropriate ELISA 
conditions. A selection of turtle sera were then tested. 
ELISA protocol: screening turtle’s sera for anti-F-US4/F-US8 7S and 5.7S IgY 
Plates for ELISA experiments were NUNC IMMUNO PLATE MAXISORP 439454 from 
Thermo Scientific. 
Wells were coated over night at 4°C with 50 μl linked casein-glutathione (ELISA diluted 1 in 
500 in coating buffer (10 mM Na2CO3, 40 mM NaHCO3 ( casein-glutathione synthesized 
according to protocol of Sehr, P. and Waterboer, T., January 2006; appropriate dilution 
determined in a GST-capture ELISA)). Then the wells were washed 3x with 200 μl PBST (0.3 
% Tween-20 in PBS). For blocking, 100 μl blocking solution (2 % milkpowder in PBST) was 
added per well and incubated at 37°C for one hour. Next, the GST-tagged antigen was added 
(cell medium supernatant containing non-purified protein, diluted in blocking buffer (1:200 for 
construct F-US4 exofuse C-myc GST, 1:100 for antigen F-US8 exofuse C-myc GST 
respectively)). The plate containing the antigen was incubated at 37°C for another hour and 
then washed twice with 200 μl PBST per well and once for 10 minutes with High salt milk (2 
% milkpowder in PBS, 0.5 M NaCl). Sera were diluted 1 in 25 in High salt milk and distributed 
to the wells, 50 μl each. It was again incubated at 37 °C for one hour, followed by three washing 
steps, 1x with high salt milk and twice with PBST. Monoclonal mouse antibodies (7S CO2; 
309 μg/ml (1:1000 in blocking solution); 5.7S D70; 461 μg/ml (1:1500 in blocking solution)) 
were added and incubated for one hour at 37 °C, 50 μl per well to detect the reaction. After 
washing (3x with 200 μl PBST), secondary antibody (goat anti mouse HRP conjugated, 1.1000 
in blocking buffer (GE Healthcare)) was added, 50 μl/well and incubated 30 minutes at 37°C. 
Plate was then washed 5x with 200 μl PBST and 1x with PBS to get rid of Tween-20 residues. 
TMB substrate (Thermo Scientific) was prepared (1:1 in dark) and added to the wells, 100 μl/ 
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well. Reaction was measured after 10 minutes at 650 nm wavelength. Reaction was stopped 
after 15 minutes using 2M H2SO4, 100 μl/well and measured again at 450 nm. 
GST-antigen titration: 
Same ELISA-protocol, but in this experiment, antigens were added in serial dilutions from 1 in 
25 up to 1 in 51200. Instead of sera, anti c-myc mc Ab was added (1 in 5000 in blocking buffer).  
Age dependent antibodies in turtle sera: 
Same protocol with the following modifications: sera were coated directly to the ELISA plate 
(coated to dryness over night at room temperature). Protein G (Thermo scientific) was added in 
place of primary antibody (1:1000 in blocking solution), as secondary antibody, HRP-
conjugated mouse anti protein G antibody (Abcam) (1:1000 in blocking buffer) was used. 
 
Sera: 
Turtle sera subjected to the ELISA for screening were collected in Australia (Ollera, Toolakea, 
JCU) (provided by Associate Professor Ellen Ariel (James Cook University, Australia)) and in 
Hawaii (Big Island, Kaneohe Bay). 
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Results 
Part 1. Construction of recombinant Baculovirus BACMIDs 
Synthetic constructs 
The Gateway technology and the BAC-to-BAC system were modified to ultimately construct 
four different baculoviruses for expressing two types of ChHV5 glycoprotein fragments. As 
outlined in Fig. 1, the predicted exodomains of two different ChHV5 glycoproteins, F-US4 and 
F-US8, respectively (Fig. 1A), were selected. In a first step (Fig. 1B), the amino acid sequences 
of these exodomains were reverse translated to a nucleotide sequence, which was optimized for 
expression in insect cells. At this stage, two variants of each exodomain were synthesized, the 
first with a C-terminal V5-6his tag, followed by a STOP codon, the second construct without 
tags and without STOP codons at their 3’ ends. All four of these constructs were flanked on 
both sides with BamHI restriction enzyme sites. In a second step, a synthetic and codon-
optimized master cassette was constructed to accommodate each of these four constructs. As 
outlined in Fig. 1C, this master cassette consisted of att recombination sites on either end, 
flanking in a 5’ to 3’ order a synthetic baculovirus signal sequence, a single BamHI restriction 
enzyme site, a c-myc tag, and a GST-tag. All five constructs were cloned into pUC57 before 
their nucleotide sequences were verified. The properties, tags, and sizes of the individual 
constructs are provided in the appendix.  
Assembly of Master cassette with exodomains 
The master cassette was PCR amplified using primers targeting some 20  nucleotides beyond 
the att sites (Tab.). The PCR product was purified by agarose gel electrophoresis, excised, and 
transferred to the Gateway entry vector pDONR221 by the BP reaction. The sequence of the 
pDONR221 comprising the Master cassette was again verified by sequencing. In a next step, 
pDONR221 containing the Master cassette was opened by BamHI restriction enzyme digestion 
and treated with phosphatase. Meanwhile, each of the four other synthetic constructs were 
excised from pUC57 by BamHI digestion. The resulting fragments were separately gel purified, 
excised, and ligated together with the linearized and phosphatase treated pDONR221 
containing the Master cassette. Four clones, each containing one of the desired  glycoprotein 
exodomains in the desired orientation within the Master cassette, were verified by sequencing 
prior to further use. These sequences are listed in the appendix. 
Transfer to pDEST8 
pDEST8 is a Gateway vector suitable to transfer by transposition the desired constructs into the 
polyhedrin locus of a baculovirus BACMID. The LR recombination reaction was used to 
transfer each of the pDONR entry clones into the destination vector pDEST8. Once more, all 
of the successful clones were subjected to sequencing. In three cases, F-US4-C-myc-GST, F-
US4-V5-6his, and F-US8-V5-6his, the full sequence could be verified. The fourth construct did 
not achieve a full sequencing overlap, leaving a gap of estimated 360 bp, which could not be 
verified. But the correct orientation of insertion could be proved. All four constructs were used 
for transposition.  
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Transposition into Baculovirus BACMIDs 
Maxiprep DNA from each construct was used to transform competent DH10Bac cells for 
transposition of the genes of interest into the baculovirus BACMID.  
Two white colonies of each construct were picked and restreaked on a fresh plate. Since all new 
colonies were white, one colony of each construct was chosen for amplification and further 
characterization. 
A PCR using the primers pUCM13 forward and pUCM13 reverse (Tab. ) was carried out and 
the PCR products were separated by agarose gel electrophoresis. In the absence of an insert, a 
product of approximately 300 bp was expected. In the present case, however, PCR products 
ranging from approximately 3800 to 4600 were observed, which essentially matched the 
expectations for Sig-F-US4-V5-6his (3980 bp), Sig-F-US4-c-myc-GST (3850 bp), Sig-F-US8-
V5-6his (4650 bp), and Sig-F-US8-c-myc-GST (4530 bp), respectively.  Accordingly, DNA 
was prepared for transfection experiments.  
Reconstitution of recombinant Baculoviruses 
Proteins of interest in fixed insect cells 
With the aim of generating infectious baculovirus from the BACMID-DNA of the four 
constructs, conventional sf9 cells were transfected using 1 µg DNA for the his –tagged 
constructs and 2 µg DNA for the GST-tagged ones, respectively. Due to the knock-out of the 
polyhedron gene, plaques indicative for recombinant baculovirus replication were difficult to 
detect. Therefore, the transfected cells were investigated using immunofluorescence using 
antibodies against the protein tags. At 96 hrs post transfection, the cell supernatant was 
harvested as the p0 viral stock. The cells were fixed and incubated with monoclonal antibodies 
(mAb against V5 or mAb against C-myc) before addition of a goat-anti-mouse IgG, conjugated 
with alexa fluor 488, to provide a green fluorescence, while the nuclei were counterstained with 
DAPI. An exemplary result is shown in Fig. 2. Approximately 5% of the cells transfected with 
Signal-F-US4-V5-6his provided a bright green fluorescence upon staining with the mcAb 
against V5, indicating that the protein of interest was being synthesized in the successfully 
transfected cells. Similar results were achieved with the other three constructs (data not shown), 
indicating that a four desired baculoviruses had been generated. The same immunostaining 
strategy was used for limiting dilution assays of the baculovirus stocks in order to determine 
the viral titers. Tab.  shows the titers achieved for P0, P1 and P2 of each construct.  
Part 2. Purification of baculovirus-expressed proteins for immunization 
 
Proteins of interest in infected cell supernatants  
According to our strategy, the proteins to be used for immunization of turtles, had been 
truncated at their C-terminus, prior to their transmembrane domains and had been supplemented 
with a synthetic baculovirus signal sequence, which was expected to guide the new proteins to 
the secretory pathway. Accordingly, a considerable portion of these proteins was supposed to 
be secreted to the cell culture supernatant, from which it could be purified. To test this 
assumption, conventional Sf9 cells or, alternatively, mimic Sf9 cells were inoculated with P2 
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of the baculoviruses at MOI5 and cell-free supernatants were harvested at 5 days post infection. 
A sample of each supernatant was separated on a polyacrylamide gel and transferred to a PVDF 
membrane, before being stained with anti-V5 mcAb as described in materials and methods. 
As shown in Fig. 3, F-US4-V5-6his provided double bands, migrating in between of the 25 kDa 
and 35 kDa markers. The observed mobility corresponded well with the predicted molecular 
weight of 24.5 kDa. While the two lower bands migrated in a similar manner, the upper band 
migrated slightly slower, when the virus was grown in mimic Sf9 cells as compared to the virus 
grown in conventional Sf9 cells. These observations suggested that the faster bands represented 
the non-glycosylated precursor, whereas the slower band represented glycosylated forms of the 
secreted fusion proteins. The additional size difference between the two slower bands may be 
attributed to the differential glycosylation strategies of the conventional Sf9 insect cells versus 
the humanized mimic Sf9 cells. Moreover, these results confirmed that the desired F-US4 
fusion protein was actually secreted to the supernatant of the infected cells.  
Similar results were obtained for the F-US8-V5-6his fusion protein (Fig. 3, lanes 3 and 4). A 
broad band migrated in between of the 55 and the 70 kDa marker bands, which fits well with 
the predicted molecular weight of 50.1 kDa F-US8-fusion protein. While in this instance the 
unglycosylated precursor did not clearly separate from the glycosylated forms of the protein, 
the fuzzy quality of the band was in accordance with the expected behavior of a glycoprotein. 
The fuzzy quality of these bands did not allow to discriminate differential glycosylation due to 
conventional or mimic Sf9 cells, respectively. In addition to the expected mature form of the 
protein, several bands running at around 15 kDa may represent break-down products of the 
fusion protein.  However, also the F-US8 fusion protein was secreted to the cell-free 
supernatant.  
Ni-purification of F-US4- and F-US8- fusionproteins  
Apart from the V5-tag, the F-US4- and F-US8 fusion proteins were also equipped with a C-
terminal 6his-tag, which had been included to facilitate protein purification.  
After optimizing the conditions for purifying the desired proteins on magnetic nickel beads 
(data not shown), T150 flasks of Sf9 or mimic Sf9, respectively, cultures were inoculated at 
MOI5 and cell-free supernatants were harvested at dpi 7. After conditioning the supernatants 
as described in Materials and Methods, they were incubated with nickel beads, washed, and 
eluted with imidazole. Samples of flow-through, final wash, and eluate were separated by 
PAGE and transferred to PVDF membrane for immunoblotting (Fig. 4). Alternatively, samples 
of the starting materials and eluates were subjected to silver staining (Fig. 5). As the exemplary 
results in Fig. 4 and 5 indicate, the desired fusion proteins were quantitatively removed from 
the starting materials and not present in the final wash but constituted >90% of the protein in 
the elution fraction.  
Using this approach a total of approximately 30 mg purified F-US4 and 40 mg purified F-US8 
protein were prepared.  
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Part 3. Analysis of the turtle’s seroresponse against ChHV5 
 
Age-dependence of antibodies in turtle sera  
While monoclonal antibodies against various turtle IgY exist (Work et al., J. Immunol. 2015), 
little is known about the presence of these IgY at different development stages of the turtles. 
Since we wanted to analyze sera of hatchlings for antibodies against ChHV5, it was of interest 
to know, which types of antibodies were actually present in the sera of hatchlings at the age of 
a few weeks. To address this question, we coated the sera of hatchlings (n=12) as well as of 
juvenile (n=22) turtles to ELISA plates. Since monoclonal antibodies against 7S (mcAb CO2) 
as well as 5.7S IgY (mcAb D70) were available to us and since it is known that protein G is 
able to bind some turtle IgY (Work et al., 2016), we coated each serum in triplicate and also in 
two different dilutions, i.e. 1:100 and 1:1000. Human serum and milk, respectively were used 
as positive and negative controls, particularly for protein G but also for establishing the 
specificity of the anti-turtle IgY antibodies in this test. The ELISA was carried out as described 
in Materials and Methods and results are shown in Fig. 6. Using the CO2 mcAb (Fig. 6A), a 
median optical density (OD) of 1 was detected with the hatchling sera coated at 1:100, a value, 
which was reduced to OD 0.35 upon coating at 1:1000. Upon coating of the sera at 1:100 from 
juveniles a median OD of 2.6 was achieved, a value, which was not significantly reduced upon 
the 1:1000 coating. Thus, the ELISA was able to detect 7S IgY in the coated sera of both 
hatchlings and juveniles. However, these observations also suggest that the maximum coating 
capacity of the ELISA plate had been achieved with both dilutions when sera from juveniles 
were used. In contrast, the hatchling’s sera did not contain enough 7S IgY to coat the ELISA 
well to saturation. The OD value was significantly reduced at the 1:1000 dilution. Upon using 
the D70 mcAb against 5.7S IgY (Fig. 6B), a median OD of 3.1 was observed with the sera from 
juveniles, a value, which was significantly reduced to OD 2.8 upon the 1:1000 dilution. In 
contrast, the sera from hatchlings achieved median ODs of 0.18 (1:100) and 0.078 (1:1000), 
which were not significantly different. These observations suggest that the ELISA did not or 
hardly detect 5.7S IgY in the sera of hatchlings, whereas 5.7S IgY were abundantly present in 
the sera of the juveniles. As expected, protein G (Fig. 6C) was able to detect some 
immunoglobulin in the turtle sera, although only in the ones from juveniles (median OD 0.59) 
and only if they were coated at 1:100. Hatchling sera at both dilutions as well as juvenile sera 
at 1:1000 provided only background values in the ELISA (median values at 0.08 to 0.09). While 
human sera were not recognized by either the CO2 or the D70 mcAb, protein G achieved an 
OD value of approximately 1.5 at a dilution of 1:100 and of 1.0 at 1:1000 (data not included in 
the Figure). In contrast, only background levels were achieved with all visualization systems, 
when milk was coated (data not included in the Figure). The serum of one single, several months 
old turtle had also been analyzed in this ELISA but the results were not included in the Figure 
because, due to its age, it did not match into any of the two groups. Interestingly, the results 
presented actually an intermediate between the two groups, suggesting that both 7S and 5.7S 
IgY develop rapidly during the first few months of life.  
In summary, 7S IgY were detected in the sera of both hatchlings and juveniles, whereas 5.7S 
IgY were detected only in the sera of the juveniles. Both monoclonal antibodies specifically 
recognized particular immunoglobulins in turtle sera and did not crossreact with either human 
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sera or milk components. Moreover, these results encouraged us to test these turtle sera for the 
presence or absence of antibodies against ChHV5.   
 
Production of F-US4-GST- and F-US8-GST fusion proteins 
The construction of the bacmids for these baculoviruses has been described in part 1. After 
transfecting the bacmids into Sf9 cells, recombinant baculoviruses were generated and titrated 
as described in part 2. The products secreted to the supernatants of conventional as well as 
mimic Sf9 cells infected with these baculoviruses were harvested and analyzed by 
immunowesternblot, using the mcAb against the C-myc tag. Exemplary results are shown in 
Fig. 7. In lanes 1 and 2, a major band of F-US4-c-myc-GST migrated at around the 55 kDa 
marker band, which corresponded with the predicted molecular weight of 47.9 kDa. This result 
confirmed that the desired F-US4 fusion protein was secreted to the supernatant of the infected 
cells. However, faster migrating bands, which may represent degradation products, could be 
observed in between of the 25 kDa and the 35 kDa markers.  
The results for the F-US8-c-myc-GST fusion protein (Fig. 7, lanes 3 and 4) were similar. A 
major band migrated in between of the 70 and the 100 kDa marker bands, which corresponded 
with the predicted molecular weight of 73.4 kDa F-US8-fusion protein. In addition, several 
faint bands running at around 70, 35 and 25 kDa may represent break-down products of the 
fusion protein.  It was concluded, that the F-US8 fusion protein was secreted to the cell-free 
supernatant. Interestingly, there was no difference in mobility between the proteins expressed 
in conventional Sf9 cells as compared to the protein expressed in mimic Sf9 cells unlike the 
construct F-US4-V5-6his produced for the immunization experiments. 
 
Titration of F-US4-GST- and F-US8-GST fusion protein antigens on casein-gluthation-
coated ELISA plates 
To test the gluthation-binding capacity of the GST-fusion proteins, an ELISA plate was coated 
with gluthation-conjugated casein as described in Materials and Methods. After washing and 
blocking, separate wells of the plate were incubated with either no antigen (solely dilution 
buffer) or with supernatant from mimic SF9 cells infected with either F-US4-c-myc-GST or F-
US8-c-myc-GST or mock-infected. Starting from a dilution of 1:25, serial 2-fold dilutions were 
applied up to the final dilution of 1:51200. After incubating and washing, the binding of the 
fusion proteins was visualized by use of a mcAb against C-myc and a peroxidase-conjugated 
anti-mouse antibody. The results are shown in Fig. 8. The 1:25 diluted supernatant reached an 
OD450 of almost 3.0, while a serial dilution of the bound fusion protein was indeed observed, 
until it reached background level at a dilution of approximately 1:1600. At the low dilutions 
(1:25 and 1:50) some background reaction of the two negative controls was observed. However, 
at 1:100, the non-specific reaction had reached background level, while the two antigens of 
interest, F-US4 and F-US8 still caused a reaction of more than 1.0 OD 450nm. These 
observations confirmed that the two fusion proteins carried a functional GST-tag, which 
allowed to quantitatively bind the native forms of the proteins to the casein-glutathion-coated 
plates.  
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Analysis of sera from Australian turtles  
Having established that the sera of hatchlings as well as of juvenile turtles from Australia 
contained antibodies that can be detected by mcAb CO2 against turtle  7S IgY, and that F-US4 
and F-US8 fusion proteins could be bound quantitatively and in a native state to ELISA plates, 
it was of interest to test these available turtle sera for antibodies against the two ChHV5 
antigens. For this purpose, ELISA plates were coated with casein glutathione, followed by 
adsorbing three different antigens and a negative control per serum, i.e. F-US4-c-myc-GST, F-
US8-c-myc-GST, canine-papillomavirus-1-capsid-protein-GST (CPV1), and supernatant from 
mock-infected insect cells. A milk solution in the place of serum was used as a negative control. 
A mcAb against GST was used to measure binding of the GST-fusion proteins to the ELISA 
plates and demonstrate absence of GST in the case of the supernatant from the uninfected cells. 
The results are shown in Fig. 9, divided into 9A, showing the reactions of the hatchlings and 
9B, showing the reactions of the juvenile turtles. Notably, the mcAb against GST caused an OD 
450 nm of 2.0445 with the F-US4 fusion protein, 1.896 with F-US8, 1.5866 with CPV1, and 
0.0925 with supernatant from uninfected cells. These data confirmed that for all three positive 
antigens ample GST-fusion protein had bound to the plates, whereas no GST was detected 
bound after incubating with the uninfected cell supernatant. The reactions of the turtle sera were 
indiscriminately low, almost exclusively below OD 0.1. The highest reaction (0.1905) was 
observed with CPV1 antigen. Statistically, there was no difference between the binding of any 
antiserum against any antigen. We concluded from this that none of the available sera contained 
any detectable 7S IgY against either F-US4 or F-US8.  
Testing of selected Hawaiian turtle sera 
Next, it was of interest to test sera from turtles with FP as well as appropriate controls for 
antibodies against F-US4 and F-US8 by using the same ELISA. For this purpose, a collection 
of 60 sera had been made available: 20 sera originated from Big Island (#1-20), where FP is 
rarely observed. 40 sera had been collected in Kaneohe Bay, where FP is observed frequently. 
20 of those latter sera came from healthy turtles (#21-40) and 20 from turtles with FP (#41-60). 
The results, sorted according to location and serum number, are shown in Fig. 10. Apparently, 
the highest reactions were observed among the turtles with FP, whereas sera from turtles 
without FP showed clearly less reaction. A quantitative analysis of the data (Fig. 11) indicated 
that turtles with FP had significantly more antibodies against F-US4 and F-US8 than turtles 
without FP. This result was true for both 7S and 5.7S IgY.  
As no gold standard for measuring antibodies against ChHV5 exists and since -- at least in the 
absence of FP -- the true individual status concerning infection with ChHV5 cannot be known, 
it was not possible to draw a reliable cut-off value for our test to discriminate infected from 
non-infected animals. However, it is remarkable that healthy animals from Kaneohe Bay 
showed barely a seroreaction, while many of the FP animals from the same location showed a 
very high seroreaction against both viral antigens. 
Discussion                                Anna Willimann 
18 
 
Discussion 
 
The Chelonid herpesvirus 5 (ChHV5) is considered the causative agent of fibropapilloma (FP) 
in marine turtles. In this project, we developed an ELISA to detect anti-ChHV5 antibodies in 
turtles against F-US4 and F-US8, respectively. F-US4 represents probably the major receptor 
binding protein, whereas F-US8, as a predicted homolog to herpesvirus gE, was suspected to 
be immunogenic but non-essential for ChHV5 replication. Furthermore, we developed another 
ELISA to detect two IgY variants in turtle sera, i.e. 7S IgY and 5.7S IgY. This was important 
in order to judge the immunocompetence of different turtle age groups. These newly created 
ELISAs were used to screen a selection of Australian hatchling and juvenile turtles for the 
presence or absence of 7S IgY and 5.7S IgY antibodies before testing them also for presence 
or absence of anti-F-US4 and anti-F-US8 antibodies. Moreover, the F-US4 and F-US8 ELISA 
was also applied on Hawaiian turtle sera, collected from animals with or without FP. Finally, 
soluble F-US4 and F-US8 antigens were produced and purified in order to vaccinate marine 
turtles for the production of reference sera.  
 
The salient features of this study are as follows: 
• Recombinant baculoviruses were constructed to express the exodomains of F-US4 and 
F-US8, respectively. The recombinant proteins, comprising a c-myc- and a GST-tag, 
were used to develop an ELISA, in which glutathione-conjugated casein was coated to 
accommodate the binding of equimolar amounts of GST-fusion proteins as ELISA 
antigen in a native state.  
• Variants of the above proteins, comprising a C-terminal V5-tag for identification 
followed by a 6xhis-tag for purification, in the place of the c-myc- and GST-tags, were 
secreted to the supernatant of baculovirus-infected insect cultures and could be purified 
to a homogeneity of about 90%.  
• Monoclonal antibodies were used to detect two particular IgY variants in turtle sera, i.e. 
the CO2 mcAb detected 7S IgY, whereas the D70 mcAb detected 5.7S IgY (Work et al., 
2015). A pilot study using Australian turtle sera revealed that sera from young hatchlings 
(approximately 4 weeks old) contained low amounts of 7S IgY, whereas 5.7S IgY 
remained undetectable. In contrast, juvenile turtles (10 years or older) had ample 
amounts of both types of antibodies. Protein-G-binding antibodies were detected at low 
amounts and exclusively in the sera of the juvenile turtles. One individual, a few weeks 
older than the rest of the hatchlings, gave signals that were between the signals of the 
two groups (hatchlings and juveniles), showing, that both 7S and 5.7S IgY develop 
rapidly during the first few months of life.  It was concluded, that immunocompetence 
was reached at the age of of about 12 weeks. This result was important for us to know, 
at what age to start with the immunization experiment. 
• Using the Casein-glutathione-GST-ELISA, the same turtle sera were also tested for 
antibodies against either F-US4 or F-US8 but with negative results. However, when 
Hawaiian turtle sera were tested in the same ELISA, high seroreactors were detected, 
particularly among animals with a high load of FP-tumors. Interestingly, tumor-free 
animals carrying clearly detectable amounts of antibodies against F-US4 and F-US8 
were hardly detected, not even among animals co-habitating in the same area as 
seropositive animals with tumors.  
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Normally, neutralization assays represent the Gold standard for serology against viruses (Holz 
et al., 2010). However, this is not possible with ChHV5 because this virus does not replicate in 
conventional cell cultures (Work et al., 2009; Work et al., 2017).  Therefore, an ELISA may 
represent a good alternative. Yet, previous attempts to establish ELISA-based serologies for 
turtle herpesviruses yielded contradictory results (Coberley, 2001; Herbst, 2008). Herbst (2008) 
developed an ELISA to detect anti-ChHV5 antibodies in turtles by using a Baculovirus-
expressed glycoprotein H (gH, F-UL22) as the coating antigen. Using captive reared green 
turtles (Chelonia mydas) with no history of virus exposure as “known negatives” and others 
with experimentally induced FP as “known positives,” this assay had, apparently, a high 
specificity but a low sensitivity. Interestingly, seroconversion in experimentally with ChHV5-
inoculated turtles was detected in only half of the animals of those bearing experimentally 
induced tumors. Indeed, antibodies were detected only in samples collected after the 
development of cutaneous fibropapillomas. However, when the same assay was applied to sera 
collected from wild green turtles in three Florida localities with different FP prevalences, 
including one site with no history of FP, approximately 80% of all sera from each single site 
gave a positive reaction against the Baculovirus-expressed glycoprotein H. As herpesviruses 
other than ChHV5 are widely prevalent among Florida green turtles (Herbst et al., 2008, 
Coberley et al., 2001), it remained unclear how these observations should be interpreted. The 
authors offered two explanations, i.e. either ChHV5 was highly prevalent among non-diseased 
turtles or a thus far undetermined herpesvirus caused a serious cross-reaction in this assay.  
In our approach, we introduced four differences to the assay developed by Herbst and 
coworkers: (1) Instead of the glycoprotein gH antigen chosen by Herbst et al. (2008), we had 
selected two different viral glycoproteins, namely F-US4, which bears a certain similarity to 
gD of other alphaherpesviruses and F-US8, which resembles gE (Ackermann et al., 2012).  
The choice of not using gH as an antigen was influenced by the knowledge that during viral 
replication the glycoprotein gH heterodimerizes with another glycoprotein gL, which leads to 
conformational changes in both of the interaction partners, which again is known to be 
associated with the formation of conformational epitopes for antibody binding (Hutchinson, 
1992)). 
Alternatively, the choice of the putative gE homolog F-US8 as ELISA antigen was influenced 
by the experience that gE of other alphaherpesviruses is known as a very strong antigen (van 
Oirschot, 1995; Weiss, 2015; Jacobs, 1994)). The marker vaccines against the Pseudorabies 
virus (PRV) in pigs and the Infectious Bovine Rhinotracheitis (IBR) virus in cattle both use gE-
deletion viruses as vaccine strains because gE is highly immunogenic but non-essential for 
replication of these viruses in cell culture, while gE-deletion viruses cannot establish efficient 
circulation in nature (Jacobs, 1994)). However, gE deletion viruses were still able to confer a 
reliable protection against disease upon superinfection with a gE-positive wild type virus. Based 
on these properties it was possible in both cases to develop vaccines, which allowed the 
discrimination of vaccinated and naturally infected animals, i.e. so called DIVA-vaccines.  
The choice of F-US4 as ELISA antigen was based on different aspects. Previously, our group 
had postulated that F-US4 may represent a homolog to gD, the receptor-binding protein of many 
alphaherpesviruses (Ackermann et al., 2012). Antibodies against the receptor-binding protein 
may be of great biological significance because they may neutralize viral infectivity. 
Accordingly, presence of such antibodies may correlate to immunological protection or else 
their absence may signify a particular vulnerability against the virus. Moreover, the nature of 
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viral receptors on host cells greatly influences the host’s susceptibility to the corresponding 
virus and is a major determinant for viral pathogenesis. Accordingly, immunity against the viral 
receptor-binding protein may correlate with immunity against viral disease.  
(2) Another difference was the binding of our antigens via their C-terminal GST-tag to the 
glutathione-casein coated plate, which enabled us to keep the antigens in native state (Sehr, 
2001 & 2002). This is in contrast to conventional ELISAs, such as those used by Herbst (2008), 
which bind their antigen directly and under denaturing conditions to the plastic surface of the 
ELISA plate (Gibbs, J., ELISA Technical Bulletin, life sciences). Antigens in their native 
conformation may be more suitable to discriminate infections with closely related viruses, for 
example the GST-fusion protein approach is frequently used in the papillomavirus field, where 
the capsid protein L1 spontaneously assembles into virus-like particles, which in turn allow the 
discrimination of infections with particular viral serotypes (Lange et al., 2009; Sehr, 2002). As 
Herbst (2008) had postulated the potential interference of a thus far undetermined chelonid 
herpesvirus, it was of interest to use the present approach with the aim to potentially avoid 
cross-reactions.  
(3) Our antigens were produced either in conventional sf9 insect cells or else in mimic sf9 cells 
to achieve a more complex, “humanized” glycosylation pattern than antigens produced in 
conventional insect cells (Thermo Fisher Scientific user guide). Indeed, antigens produced from 
mimic sf9 cells had a higher molecular weight than those produced from conventional sf9 cells 
(see Fig. 3), which may be important both for inducing and detecting a specific antibody 
response in turtles, since turtles, similar to mammalians, make use of a more complex 
glycosylation pathway than insects (Hirokazu Yagi, 2010).  
(4) While Herbst et al (2008) tested only for 7S antibodies against ChHV5, we extended the 
range of antibodies to both 7S and 5.7S. As reported previously, a 5.7S antibody response 
develops much more slowly than a 7S antibody response and may be indicative for a chronic 
antigenic stimulation (Herbst and Klein, 1995; Work et al., 2000; Work et al., 2015). Before 
screening sera of turtles of different age groups, namely hatchlings, juveniles and adults, for the 
presence of anti-ChHV5 antibodies, we wanted to know, if both types of IgY are present in the 
sera of juveniles and especially hatchlings in the first place. So we developed an ELISA to 
detect these two particular antibody types, 7S and 5.7S IgY in the sera of these two age groups. 
We detected that hatchlings had low amounts of 7S IgY, while 5.7S IgY were below the limit 
of detection in the same sera. In contrast, both 7S and 5.7S IgY were readily detected in the 
sera of juvenile turtles (Fig. 6). In agreement with previous studies, we were able to confirm 
that some IgY in turtle sera can be detected by protein G (Work et al., 2015). However, the 
amounts of protein G-binding IgY were low in the juveniles and below the detection limit in 
the hatchling sera. Importantly, this series of experiments also confirmed previous reports that 
our anti-IgY monoclonal antibodies actually were specific for turtle IgY and did not cross-react 
with immunoglobulins of other animal species (Work et al. 2015).  
One of the difficulties in our study was that we did not get permission for experimental 
inoculation of turtles with ChHV5 in order to obtain a collection of gold-standard sera, which 
would allow us to clearly discriminate seronegative from seropositive. However, we used a 
control antigen, comprising the tags (c-myc and GST), which was able to bind to casein-
gluthatione-coated ELISA plates. The c-myc tag, present on each variety of ELISA antigen, 
was further used to coat comparable amounts of antigens to the plate. Since each gluthatione 
molecule can bind one GST-counterpart and each fusion protein comprised one singly c-myc 
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epitope, dilutions of each antigen were incubated on casein-gluthatione-coated ELISA plates 
before the amount of bound antigen was determined using an mcAb against c-myc. Afterwards, 
each antigen was diluted in a manner to give an equal ELISA reaction upon testing with the c-
myc mcAb, thus, providing equimolar coating of each antigen. On one hand, a serum was 
considered positive, if its reaction was obviously stronger with the ChHV5-fusion protein than 
with the fusion protein without ChHV5-part. On the other hand, a serum was considered 
negative, if the reactions against the ChHV5-less antigen did not greatly differ from its ChHV5-
containing counterpart. Thus, while a clear cut-off value to discriminate between positive and 
negative could not be established, it was possible to discriminate between sera with strong 
reactions and sera with weak or no reactions against the ChHV5-containing antigen. 
Based on these conditions, the results of our study were only in part consistent with the previous 
findings by Herbst and others (2008). Consistent with that study, we did not detect ChHV5 
antibodies in captive reared turtles without history of FP. Moreover, clearly seropositive 
animals were found almost exclusively among animals with FP, which is coherent with Herbst’s 
finding that experimentally infected animals developed antibodies only after the development 
of tumors. Yet in stark contrast to that previous study, where more than 80% anti-gH-antibody-
positive animals existed among populations without history of FP, our assay did not detect 
many FP-negative but ChHV5-seropositive animals in the wild. Interestingly, this was true for 
sera taken either from Hawaiian or from Australian turtles. Notably, most sera that were 
considered “positive” reacted equally strong against the F-US4- and the F-US8-fusion protein. 
Moreover, 7S and 5.7S reactions were equally often detected but, in general, the 5.7S IgY gave 
stronger reactions than the 7S antibodies. Antigens produced on conventional Sf9 cells created 
some more background reaction than antigens produced on Sf9 mimic cells but neither cell type 
did give rise to conflicting results.  
The general scarcity of clearly seropositive individuals among Hawaiian and Australian turtles 
came as a surprise. Herpesviruses that freely circulate among humans and other animals provide 
usually a serological prevalence of higher than 50%, which includes a majority of individuals 
without disease signs (Wald, Corey, 2007). For example, a recent study on the prevalence of 
antibodies against human herpesviruses among Swiss people without any disease signs revealed 
that over 50% had antibodies against HSV-1 and HCMV, whereas the seroprevalence of healthy 
individuals with antibodies against VZV, EBV and HHV6 was higher than 80% (Barandun, 
2014). Only HSV-2 and HHV8 showed seroprevalences of 20% or less, which was to be 
expected since, due to their biological properties, both of these viruses do not circulate freely 
among the Swiss population (Bünzli, 2004; Regamey, 1998). 
Together, these observations and considerations may contribute to an already controversial 
discussion about the prevalence, disease-causing role, and natural reservoir of ChHV5. 
According to one scenario, which is at least in part supported by Herbst’s (2008) serology data, 
ChHV5 is widely distributed and causes FP only in a few of many infected animals. Consistent 
with this, a variety of groups has reported frequent detection of ChHV5 DNA on the skin of 
seemingly healthy turtles. Interestingly, this finding is confirmed predominantly among groups 
that work on Atlantic and Caribbean turtles (Page-Karjian, 2012; Alfaro-Núñez, 2014). In 
contrast, groups working on Pacific turtles, with most studies around the Hawaiian Islands, 
were consistently unable to detect ChHV5 DNA from non-tumorous tissues (Work, 2015). 
Fascinatingly, this discrepancy is now mirrored in the serological studies, which suggest high 
prevalence of the virus in Florida and very low prevalence in Hawaii and Australia. As 
explanation for this seeming contradiction one may argue that over decades, the treatment of 
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animals with FP has been vastly different for either the Atlantic or the Pacific turtle population. 
While Pacific turtles with FP were left without treatment or were euthanized, surgical removal 
of FP tumors has been quite common to treat Atlantic turtles (Brunner, 2014). Ultimately, this 
may have led to the development of a ChHV5 variant virus, which is high contagious and, thus, 
highly prevalent but probably less virulent with regard to causing FP. Such a variant, which 
would be restricted to the Atlantic areas might explain the different prevalence findings in 
Atlantic and Pacific regions. 
However, these considerations lead also to an alternative scenario, according to which a virus 
with high similarity to ChHV5 may exist, though circulating only among Atlantic turtles, which 
could be responsible for the serological cross-reactions observed among Florida turtles and 
which could explain the detection of viral DNA on the skin of healthy animals in these regions. 
Indeed, herpesviruses other than ChHV5 have frequently been detected among Atlantic turtles 
but do apparently not circulate among Hawaiian or Australian turtles (Stacy, 2008). If this 
second scenario were true, the question would arise as to whether or not ChHV5 is actually a 
turtle virus. It is difficult to perceive that ChHV5 has been able to mount an FP-pandemic with 
only so few animals excreting and transmitting virus (Work et al., 2015). An obvious 
explanation for this would be that animals other than turtles may represent the true virus 
reservoir. Indeed, thus far only two reports exist, which conceivably describe the replication of 
ChHV5 in turtle tissue (Work et al., 2015; Work et al., 2017). 
Consistent with the above considerations, we did not detect anti-ChHV5 antibodies among a 
selection of Australian turtles, neither in hatchlings nor in juvenile individuals from different 
locations (Fig. 9).  
For the immunization experiments in order to raise reference sera for our serological assay, it 
was planned to immunize turtles with either purified F-US4 protein or purified F-US8 protein. 
Originally it was planned to immunize juvenile turtles for the purpose of collecting reference 
sera. Unfortunately, the permission by the Australian authorities requested euthanasia of all 
vaccinated animals at the end of the experiments. Because only a small percentage of turtle 
hatchlings reaches the age of those juveniles (http://oceanservice.noaa.gov/), and because of the 
high value of these animals for future breeding, it was decided to immunize turtle hatchlings in 
the place of the juveniles, because their replacement is easier. Regarding immunizing hatchlings 
there are three issues that have to be considered. 1. To date, to our knowledge, there are no 
reports about vaccinating turtle hatchlings, only reports about successful immunizations of 
juvenile turtles are available (Benedict & Pollard, 1972; Work et al., 2000), 2. newborn animals 
are usually not fully immunocompetent (Hodgins, 2012). In reptiles the development of the 
immune system is even slower. It was detected, that the snapping turtle’s complete 
immunological competence occurred only a few month after hatching (El Deeb, 1990). In 
previous studies about spirorchiid infection in green turtles, it was found, that hatchlings had 
significantly lower titers of 7S IgY against some spirorchiid antigens compared to juvenile 
turtles or adults (Work et al., 2005).  Our investigations about the presence of immunoglobulins 
in turtle hatchlings confirmed that hatchlings may have IgY of the type 7S, though to a much 
lesser quantity than juvenile turtles. Work et al. suggested, that the low antibody titers in 
hatchlings against the spirorchiid antigens might represent maternal antibodies transferred to 
the offspring, because hatchlings are very unlikely exposed to trematode cercariae before 
leaving the nesting beach (Work et al., 2005). And this leads to the third issue regarding 
immunizing turtle hatchlings: 3. maternal antibodies, transferred from the mother to the 
offspring might interfere with the immunization process (Hodgins, 2012). But if the mother was 
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not ChHV5-seropositive, the hatchlings are not likely carriers of anti-ChHV5 antibodies. 
Specific antibodies against our two viral antigens F-US4 and F-US8 were not detected in our 
experiment. Therefore interference of maternal antibodies with the vaccination process had not 
to be expected in our case. Still, due to the lower immunocompetence at the time of the first 
immunization, there is a risk, that hatchlings develop an immunetolerance against those two 
particular antigens (Piccand, 2016; Sanchez-Schmitz, 2011). In our ELISA testing for the 
presence of IgY in turtle sera, the serum of one single, several months old turtle had also been 
analyzed but this results were not included in the Figure because of its higher age compared to 
the other hatchlings (around 4 weeks old). This turtle did not match into any of the two groups. 
Interestingly, signals detected were actually between the signals of the two groups, suggesting 
that both 7S and 5.7S IgY develop rapidly during the first few months of life. The higher 
antibody level compared to the younger hatchlings found in this specific turtle are clearly the 
result of own antibody production and shows the stage, where immunocompetence was reached. 
Therefore we found the right age of turtle hatchlings to start with the immunization process.  
The proteins designed for that purpose were expressed in the cell culture supernatant, from 
which they could be purified on magnetic nickel beads under native conditions to a 
homogeneity of about 90%. With this purity, the vaccine was ready for the immunization 
experiments on turtles. 
 
Conclusions: 
We were able to develop an ELISA, in which glutathione-conjugated casein was coated to 
accommodate the binding of equimolar amounts of GST-fusion proteins as ELISA antigen in a 
native state. Results were reproducible and equally strong against the F-US4- and the F-US8-
fusion protein. With our assay, clearly seropositive animals were found almost exclusively 
among animals expressing FP tumors, whereas FP-negative but clearly ChHV5-seropositive 
animals in the wild were barely detected. This was the case for sera taken from Hawaiian and 
from Australian turtles. The scarcity of clearly seropositive individuals among Hawaiian and 
Australian turtles was surprising and led to the conclusion that ChHV5 was either not 
circulating openly in the turtle population or antibody titers of seropositive but tumor-free 
animals were very low. Our immunization experiments, which are in progress, will eventually 
lead to the production of reference sera may help to draw a cut-off value to distinguish between 
seropositive and seronegative animals. 
The ELISA results detecting turtle antibodies against two viral glycoproteins F-US4 and F-US8 
of ChHV5 allowed further discussion about the prevalence and the natural reservoir of ChHV5. 
Different scenarios explaining the different prevalence findings in Atlantic and Pacific regions 
are possible. 
The different treatment strategies of FP animals from either Atlantic or Pacific regions may 
have led to the development of a ChHV5 variant virus, which is very contagious and therefore 
highly prevalent among Atlantic turtle populations. Another possibility to explain the different 
prevalence findings in Atlantic and Pacific regions is the existence of a virus other than ChHV5 
with high similarity to ChHV5 circulating among Atlantic turtle populations, leading to 
serological cross-reactions. These considerations led to the suggestion, that animals other than 
turtles may represent the true virus reservoir for ChHV5. In future experiments it would be 
interesting, to use our assay on sera of Atlantic turtle populations to see, if high prevalence 
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could be confirmed as previously tested (Herbst et al., 2008; Stacy, 2008). Moreover, other viral 
antigens could be expressed and used with the same ELISA protocol, in order to find a tool to 
distinguish FP-negative but ChHV5-seropositive animals from FP-negative animals that had 
never encountered ChHV5.  
Additionally it would be interesting to test, if antibodies against F-US4 upon immunization are 
protective against development of the disease. This would be a first step towards control of the 
disease by using a vaccine containing F-US4 as an antigen. 
Our finding that hatchlings have originally very low IgY concentrations in their sera and that 
these increase only several months after hatching, indicates that very young turtles are probably 
not fully immunocompetent and that too early vaccination may lead rather to tolerance than to 
immunity. Therefore, we suggest to vaccinate hatchlings in the future not before 6 months of 
age.  
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Figures 
 
 
Fig. 1. Strategy of vector construction. 
(A) Schematic representation of the F-US4 glycoprotein, inserted into a membrane (orange bar). 
The cytoplasmic tail (below the membrane), the transmembrane region, and the signal sequence 
(in red) were excluded from the construct, which thus comprised exclusively the domain 
protruding from the outer side of the membrane (exo-domain). (Pictures exported from 
PROTTER, Protter: interactive protein feature visualization and integration with experimental 
proteomic data. Omasits U, Ahrens CH, Müller S, Wollscheid B. Bioinformatics. 2014 Mar 
15;30(6):884-6. doi: 10.1093/bioinformatics/btt607.) 
(B) The amino acid sequence of the F-US4 exodomain (and F-US8; not shown) was reverse 
transcribed in silico, optimized for expression in insect cells, and synthesized in frame with two 
C-terminal epitope tags, namely V5 and 6-his. The entire construct was flanked by BamHI sites 
to fit the cassette into the construct in (C). The V5-6xhis tail was followed by a STOP codon. 
A variant of this construct was synthesized, in which the V5-6xhis tags were deleted and which 
came without STOP codon to provide a fusion protein with the C-terminal C-myc-GST tail. 
Similar variants were constructed for the F-US8 exodomain (A'). 
(C) The Signal-C-my-GST construct was synthesized to be flanked by attB1 and attB2 sites, 
respectively, for transposition into the Gateway entry vector pDONR221. It also contained one 
single BamHI site in between of the synthetic baculovirus signal sequence and the C-myc tag, 
which served to accommodate insertion of various BamHI fragments, whose amino acid 
templates are depicted in A and A'. (Pictures B and C exported from CLC Main Workbench 7) 
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Fig. 2. Identification of recombinant baculoviruses. Sf9 cells were transfected with 1 µg bacmid 
DNA and propagated for 96 hrs. One replicate sample of the transfected cells was fixed with 
4% PFA for 15 minutes and permeabilised in PBS, 0.1% Triton-X100 before anti-V5 
monoclonal antibody was added, followed by alexa fluor 488 goat-anti-mouse (green 
fluorescence). The nuclei of the cells were counter stained with DAPI (blue fluorescence) prior 
to analysis under the fluorescence microscope. (Magnification: 20x; bar) 
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Fig. 3. Detection of V5-fusion proteins by Western immunoblot. Supernatants of baculovirus 
(lanes 1 and 2: F-US4-V5-6his; lanes 3 and 4: F-US8-V5-6his) inoculated cell cultures (Sf9 
cells: lanes 1 and 3; mimic Sf9 cells: lanes 2 and 4) were separated by PAGE, transferred to 
PVDF membranes and immunostained with anti-V5 mcAb. Lane M: protein ladder with 
molecular weights indicated on the right.  
 
 
Fig. 4. Ni-purification of fusion proteins. Samples of the flow through fractions (lanes 1, 4), 
final washes (lanes 2,4), and eluates (lanes 3, 6) of magnetic nickel bead purification were 
separated by PAGE, transferred to PVDF membranes and immunostained with anti-V5 mcAb. 
Lane M: protein ladder with molecular weights indicated on the right.  
Figures                                Anna Willimann 
28 
 
 
 
Fig. 5. Fusion proteins before and after Ni-purification. Samples of the starting materials (lanes 
1) and of the final eluates (lanes 2) of the F-US4-V5-6his (A) and F-US8-V5-6his (B) fusion 
proteins were separated by PAGE and subjected to silver staining. M indicates the molecular 
weight marker. Relevant MWs are indicated on the left of the pictures. The arrows point to the 
purified products.  
 
 
 
Fig. 6. Age dependent antibodies in turtle sera.  
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Fig. 7. GST-fusion proteins as ELISA antigens. Detection by Western immunoblot. 
Supernatants of baculovirus (lanes 1 and 2: F-US4-C-myc-GST; lanes 3 and 4: F-US8-C-myc-
GST) inoculated cell cultures (Sf9 cells: lanes 1 and 3; mimic Sf9 cells: lanes 2 and 4) were 
separated by PAGE, transferred to PVDF membranes and immunostained with anti-C-myc 
mcAb. Lane M: protein ladder with molecular weights indicated on the left.  
 
Fig. 8. Dilution of GST-antigens on casein coated plates. Detected by anti-C-myc-mcAb 
reaction 
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Fig. 9. GST-ELISA (mcAb CO2 against 7S IgY).  
anti-GST antibody reacted as follows (OD450) with the four antigens: 
F-US4: 2.0445  
CPV: 1.5866  
uninfected supernatant: 0.0925  
F-US8: 1.896  
 
Fig. 10. F-US4-GST-ELISA using sera from turtles with or without tumor. 
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Fig. 11. Association of fibropapillomatosis with antibodies against ChHV5.  
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